Seizures in the general population after intravenous contrast med ia administration are rare, occurring in about 0.01 % of patients [1] . However, their inciden ce is reported as 6 % -19 % in patients with brain metastases undergoing contrast cerebral computed tomography (CT) [2, 3] . We undertook a prospective, randomized study to identify risk factors in these patients and assess the value of the prophylactic use of diazepam before intravenous contrast media administration during cerebral CT in an attempt to assess its effect on seizure incidence in this patient population.
Subjects and Methods
A total of 284 consecutive patients with known or suspected brain metastases underwent contrast cerebral CT. Th ey were randomiz ed with eve ry other patient receiving 5 mg of diazepam (Valium, Roc he) immediately before co ntrast injection : 142 patients (diazepam group) received di azepam while 142 patients (nondiazepam group) did not. Diazepam was ad mini stered as a slow intravenous injection over at least 1 min and followed imm ed iately by th e contrast med ia. In 26 patients , CT was performed immediately after receiving 300 ml (40 g iod ine) of meglumine diatrizoate by a slow drip infu sion techniqu e. In 258 patients , a 1 hr delayed CT scan was obtained after receiving 600 ml (80 g iod ine) of 30 % meglumine diatrizoate (Reno-M-Dip , Squibb) as an imm ed iate 300 ml bolu s given over 4-9 min and followed by a 300 ml drip infu sion during the next 10-15 min [4] . Wh en a pati ent developed a se izure, the ad mini stration of contrast media was stopped imm ed iately and treated appropri ately . A seizure was defined as paroxysmal , un controll ed motor activity , which was eith er fo cal or generali zed and followed by an alterati on of co nsciousness [5] . The patient's medical records and CT scans were analyzed to determine: (1) primary mal ignancy; (2) number, type, and duration of prior seizures and anticonvu lsant therapy at the time of the CT scan; (3) prior or concurrent central nervous system (CNS) therapy; ( 4) presence, site, activity, and number of brain metastases; and (5) contrast media dosage and administration techn ique. Particu lar attention was paid to the clinical and CT features of the patients who developed seizures after contrast media administration . The exact amount of the contrast media administered and the time of development of the seizures after the start of constrast media infusion were noted .
The patients in th e study population were 14-78 years old; there were 121 males and 163 fema les . Underlying primary malignancies and their frequen c ies are listed in table 1 .
Results
Ninety-si x of the 142 patients in the diazepam group and 92 of the 142 patients in the nondiazepam group had brain metastases id entified on CT . The other patients in each group had no rel evant abnormalities detected on CT . Three (3 % ) of th e 96 patients with brain metastases on CT in the diazepam group and 14 (15 % ) of the 92 patients w ith brain metastases on CT in th e nondiazepam group developed focal or grand mal seizures after contrast media adm inistration ( 
Number, Type, and Duration of Prior Seizures and Anticonvulsa nt Th erapy
The three patients in the diazepam group with brain metastases who developed seizures after contrast media had a previous history of seizures caused by metastatic disease. These seizures occurred from 1 day to 7 months before contrast CT. Two of these three patients had therapeutic blood levels of diphenylhydantoin (Dilantin, ParkeDavis) at the time of CT , whi le one had subtherapeutic levels. Of the other 93 patients w ith brain metastases in the diazepam group who d id not seize w ith contrast, 13 had a prior seizure history caused by their metastases disease that had been d iagnosed on prior CT or radionuclide brain scans from 1 day to 11 months previously. Eight of these 13 patients had therapeutic blood levels of diphenylhydantoin while five were receiving no anticonvulsant therapy at the time of CT .
Of the 14 patients with brain metastases who did not rece ive diazepam but who developed seizures at the time of CT, 10 had a prior seizure and four had their first seizures at the time of the contrast CT . The seizure history in the 10 patients ranged from 1 day to 3.5 months prior to CT . Eight of these 10 patients had therapeutic blood leve ls of diphenylhydantoin while two did not. A se izure history due to metastatic disease was present in 21 of the other 78 patients in the nondiazepam group with brain metastases who did not seize at the time of CT. Seizures were noted in this group from 2 days to 6 months before CT . Therapeutic anticonvulsant blood levels were present at the time of CT in all 21 of these patients.
Eighty of the 284 patients had prior contrast cerebral CT scans from 1 week to 11 months preceding entry into the present study. Five of the 80 patients developed seizures at the time of their previous contrast CT . Two of the five were randomized to the diazepam group and three to the nondiazepam group during the present study . They all developed seizures at the time of CT during the present study irrespective of th eir diazepam group randomization . Of the three patients in th e nondi azepam group who seized before and after entry into th e prese nt study , one had a grand mal seizure at the time of both CT scans . The other two patients had focal seizures during both CT studies. All three patients had CT evidence of progressive cerebral metastatic disease. The two patients in the diazepam group who seized at the previous and present CT scans had grand mal seizures in both instances. The seizures after diazepam were of subjectively lesser clinical severity (shorter duration and lesser magnitude of motor activity) than at the time of the previous scan.
Prior or Concurrent CNS Therapy
Two of the three patients in the diazepam group with brain metastases and seizures had prior total brain irradiation (2,000-3 ,600 rad [20- 30 Gy] in 10-18 fractions) 2-7 months before CT. One of these two patients was also receiving intrathecal methotrexate and cytosine arabinoside for treatment of CNS leukemia at the time of CT . The third patient had received no prior CNS therapy. Of the other 93 patients in the diazepam group with brain metastases and without seizures at the time of CT, 24 had a history of brain metastases. Of these 24 patients, 13 had received 2 ,000-4,600 rad (20-46 Gy) in 10-28 fractions from 1 to 8 months before CT . Eleven of these 24 patients had ongoing CNS radiotherapy at the time of CT .
Of the 14 patients in the nondiazepam group with brain metastases and seizures at the time of CT, eight had prior total brain irradiation (1,800 to 2,400 rad [18-24 Gy] in 8-12 fractions) 1 .0 -3.5 months before CT. The other six patients in this group had no prior brain irradiation. None of the 14 patients had intrathecal chemotherapy . Of the remaining 78 patients in the nondiazepam group with brain metastases and without seizures at the time of CT , 21 had a history of brain metastases and were treated (2 ,000-4,600 rad [20- 46 Gy] in 10-32 fractions) 1-10 months before CT. None of the 46 patients in the diazepam group and none of the 50 patients in the nondiazepam group without brain metastases on CT had prior brain metastases or radiotherapy.
Presence, Site, Activity, and Number of Brain M etastases on CT
The CT appearance in the patients with brain metastases were identical in the diazepam and nondiazepam groups. The abnormalities consisted of single or multiple regions of increased attenuation with surrounding edema in the cerebral and / or cerebellar hemispheres after constrast media administration . There were no characteristic CT abnormalities in the patients who developed contrast media-associated seizures to distinguish them from patients who did not seize. Metastases were seen in all but one patient who seized. This latter patient received diazepam and developed status epilepticus 1 hr after contrast media injection. CT was not performed . An autopsy 48 hr after contrast injection demonstrated a focal cerebellar meningeal metastasis from breast carcinoma. There were no brain parenchymal metastases identified. Table 3 relates the status of the brain metastases to the presence or absence of contrast-associated seizures for the diazepam and nondiazepam groups . All seizures in both groups occurred in patients with either newly diagnosed metastases or in patients with progression in number or size 13 .
• Exc ludes one pati ent to whom an unknown amoun t of contras t malerial wa s administered prior to deve lopment 01 seizure ac tivit y.
of CNS metastases during therapy. Seizures did not occur in patients demonstrating a response (as determined by serial CT scans) to CNS antineoplastic therapy.
Contrast Media Dosage and Administration Technique
Of the 284 patients under study , 258 received the high 80 g iod ine dose and 26 received the 40 g iodine dose. Table 4 shows the grams of iodine administered by the time of onset of seizure activity in 16 of the 17 patients with seizures . Thirteen patients se ized with 40 g or less of iodine and three seized after receiving 41 to 80 g of iodine. Of th e 258 patients who received the 80 g iodine dose, 173 had brain metastases. Of these 173, 91 were in the diazepam group and 82 were in the nondiazepam group. Three of the 91 patients in the diazepam group and 12 of th e 82 patients in the nondiazepam group developed contrast-induced se izures. Of the 26 patients who received the 40 g iodine dose, 15 had brain metastases. Five of these 15 patients were in the diazepam group and 10 were in the nondiazepam group. Two of the latter 10 patients developed contrast-induced seizures.
Contrast-associated seizures were successfully treated with varying amounts of intravenous diazepam in all but th e one patient previously described with a cerebellar meningeal metastasis at autopsy who di ed in status epileptic us. No serious adverse side effects were produced by the diazepam administration.
Analysis of our data demonstrated that factors that had a statistically significant effect · on the incid ence of contrast media-associated seizure were : prior ~eizure history, prior or concurrent CNS antineoplastic therapy , the presence of brain metastases, and the intravenous administration of 5 mg of diazepam. Table 5 lists a series of conting encies showing the distribution of study patients categorized by the above factors. In the group without metastases, five out of eight possible entries were empty and no contrast mediaassociated seizures were noted among the 96 patients without brain metastases in both the diazepam and nondiazepam groups. For these reasons , evaluation of the effect of diazepam within the group without metastases was not possible and the analysis was limited to the group with brain metastases.
The randomization used failed to obtain comparable groups in the category positive for both seizure history and prior or concurrent CNS therapy . The diazepam group had 15 such patients while the nondiazepam group had 29. To adjust for this difference, log it analysis [6 , 7] with seizure as the outcome was used to identify models which best " fit " 5 shows that for this group of patients the admin istration of diazepam tended to reduce the risk of contrast media-associated seizures, while seizure hi story or previous or concurrent CNS therapy tended to increase this risk .
Using the Mantel-Haenszel method [8] of estimating the odds ratio (approximate relative risk) by looking at table 2 as four separate 2 x 2 contingency tables , we estimate the odds rati o to be 3 .9 . Thus the risk of contrast mediaassoci ated seizure was about 3 .9 times greater in the nondiazepam group than in the di azepam group.
Using the logit analysis desc ribed previously , the status of metastases (table 3) was found to be significantly associated with th e risk of seizure ( X 2 = 28.17 , 3 df, p < 0 .0005). The pati ents with progression of CNS metastatic di sease during CNS antineoplastic therapy had a much higher risk of c ontrast-associated seizure than either pati ents with newly diagnosed metastases or patients showing a response to therapy.
Discussion
The reported incidence of contrast media-associated seizures during cerebral CT in patients with brain metastases is 6 %-19% [2, 3] . In our series, seizures occurred in 15% of patients who did not receive prophylactic, preconstrast diazepam. The administration of a 5 mg intravenous bolus of diazepam immediately before contrast media injection decreased this seizure incidence to 3 %. Indeed, the relative risk of developing a contrast media-associated seizure was about 3 .9 times greater in the nondiazepam than in the diazepam group. Previous seizure history and either prior or concurrent CNS antineoplastic therapy had a statistically significant effect in increasing the risk of contrast mediaassociated seizures. The risk of developing such a se izure was also statistically significantly increased in those patients with progressive cerebral metastases who underwent contrast cerebral CT . No relation was observed between the underlying primary malignancy; number, site and CT appearance of brain metastases; and contrast media dosage and the risk of developing a contrast media-associated seizure . The patient population potentially benefiting from the prophylactic injection of diazepam before contrast media administration includes any patient with either known or suspected brain metastases.
It should be noted that anticonvulsant medication (diphylhydantoin), which is satisfactory by clinical and biochemical criteria, did not protect against contrast media-provoked seizures in 23 % of patients with brain metastases who were receiving this medication. We consider preconstrast prophylactic diazepam administration a safe and efficacious manner to prevent or diminish this complication of iodinated contrast media adm inistration in patients with brain metastases.
Drowsiness and leth argy are the most common diazepam side effects. Occasionally, transient ep isodes of hypotension, bradycardia , or apnea are noted after its admin istration [9] . The latter, more serious side effects are most likely to develop in the elderly or very ill patients and those with limited pulmonary reserve [9] [10] [11] [12] [13] [14] . It is important to inject diazepam slowly, taking at least 1 min for each 5 mg administered (Valium Comprehensive product information, Roche Labs.). Concomitant use of barbiturates increases CNS depression with increased risk of these serious side effects, espec ially apnea [15, 16] .
Experiments in feline and simian models have shown that diazepam increases the inhibitory mechanisms that arrest or suppress epileptiform activity from experimentally induced seizure foci [17] [18] [19] . The postulated mechanism of diazepam action is through enhancement of postsynaptic inh ibition mediated by the neurotransmitter gamma aminobutyric acid (GABA) [20] [21] [22] [23] .
The exact mechanism of contrast media seizure induction is unknown . Certain factors , however, influence contrast media neurotoxicity. Contrast media consistently indu ce seizures in patients when injected in large amounts into the subarac hnoid space [24] or rapid ly and repeatedly in high Middle row: high-dose contrast scans 1 hr after infusion illustrate metastalic foc us (arrowh eads ) and enh ancement of motor co rtex . Bottom row: findings intensified on 2 hr delayed scans. Despite persiste nt acc umu lation of contrast media, palient did not seize. Window setting s were adjusted to maximize enhancement. Intensity of contrast enhancemenl should be compared with norm al co rtex of left hemisphere. osmolar solutions (1 ,000 mosm / I) jnto the carotid artery [25] . However, the same contrast media given intravenously cause a seizure in only one of every 10,000 patients undergoing excretory urography [1] . This incidence of intravenous contrast media-associated seizures increases 600-to 1 ,900-fold if the patient population receiving the contrast media is restricted to those with brain metastases [2, 3] . An even greater 3,000-fold increase will occur if the patient population is limited to those with brain metastases and either a seizure history (caused by the neoplasm) and / or prior or concurrent CNS antineoplastic therapy. Clearly, it is a preexisting seizure foc us in patients with brain metastases that allows the intravenous adm ini stration of contrast media to induce a seizure. Furthermore, this focu s is peculiar to the metastatic lesion , as patients with either other focal brain lesions, such as infarctions, or epi leptic foci , such as in idiopathic epilepsy , have a much lower risk of intravenous contrast media-associated seizures.
While it is not clear precisely how contrast media induce seizures, it is obvious that extravasation of contrast media into the brain, which has been linked to contrast med ia neurotoxicity after intrathecal [25] and intracarotid [17] administration, is not the sole determinant of neurotoxicity after its intravenous administration. Indeed , three of the seven patients in a series by Scott [3] who seized after intravenous contrast media infusion had no CT detectable brain enhancement. Conversely, contrast media extravasation may be massive in patients with cerebral neoplasms, as seen in our and other se ries [26] , without inducing seizu res. In addition , the rapid high-iodine dose tec hnique, which produces increased CT enhancement of a variety of cerebral lesions due to greater contrast media extravasation into th e brain , as compared with 40 g iodine doses, is not associated with an increased incidence of sei zures , as witnessed by the data in this seri es (table 4) . Cl early, the route of contrast media administration and the particular type of underlying brain pathology are important neurotoxic dete rminants of contrast media. Contrast medi a extravasation into th e brain per se after its intravenous injectio n is not a suffi cient explan ation for its mec hani sm of neurotoxicity .
The vasog eni c brain edema that accompanies metastases produces a local slowing of the cereb ral c irc ul ation. Fischer [27] postulated this produces a prolonged exposure of vascul ar endothelium to contrast media, thus allowing a greater opportunity for co ntrast material to exert its direct " permeability changing effect. " This allows con trast extravasation , which , he postulates, is the probable cause of seizures in patients with metastases. However, this focal slowing of the cerebral circulation produces a relative degree of ischemi a at the margi n of th e edematous brain surro unding a metastasis. Thi s ischem ia may damage vascu lar endothe liu m, increase blood-brain barri er permeab ility, and allow contrast media leakage. Ind eed , the observed pattern of enhancement at th e edema margin ( fig . 1 ) occu rs in the' gray matter and is identical to that seen in strokes and transient ischemic attacks [28] . Pathologic examination of these regions demonstrates small focal cortical infarcts corresponding to the CT contrast enhancing regions [28] . In our series, none of the patients with contrast-associated seizures had the described gray matter enhancement surrounding peritumoral edema, and numerous other patients did have this pattern and did not seize . Therefore, the theory postulated by Fischer does not appear to be an adequate exp lanation.
Many chem ical and physical potentially neurotox ic features of contrast media have been intensively studied. Contrast media seizure induction has occurred with similar frequency in our and other series [2 , 3] that used contrast media containing both sodium and meglumine diatrizoate and iothal amate, varying in osmolarity from 643 mOsm / 1 to 2,150 mOsm/1 and containing 14%-40% iodine. This wide range of physical and chemical properties indicates that such properties are not important determinants of seizure production after intravenous contrast media injection.
